Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 34Carboplatin 32pembrolizumab 28Pemetrexed 27Magnetic Resonance Spectroscopy 27Cisplatin 22Paclitaxel 15Gemcitabine 13durvalumab 12Docetaxel 12osimertinib 11Nivolumab 11atezolizumab 8Immunoglobulin G 8Disulfides 8Taxes 7Etoposide 7130-nm albumin-bound paclitaxel 7Radiotherapy 6Radiosurgery 6Radiation 6Platinum 6Cetuximab 6Biopsy 6X-Rays 51,2-diaminocyclohexaneplatinum II citrate 5Ramucirumab 4Observation 4Irinotecan 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × iadademstat × 30 days × Clear all
NCT06287775 2026-05-22

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡